Exelixis Inc (EXEL)
23.70
+0.16
(+0.70%)
USD |
NASDAQ |
Apr 26, 16:00
23.70
0.00 (0.00%)
After-Hours: 20:00
Exelixis Cash from Operations (TTM): 333.32M for Dec. 31, 2023
Cash from Operations (TTM) Chart
Historical Cash from Operations (TTM) Data
Date | Value |
---|---|
December 31, 2023 | 333.32M |
September 30, 2023 | 396.45M |
June 30, 2023 | 389.15M |
March 31, 2023 | 299.30M |
December 31, 2022 | 362.61M |
September 30, 2022 | 385.37M |
June 30, 2022 | 358.61M |
March 31, 2022 | 508.98M |
December 31, 2021 | 400.80M |
September 30, 2021 | 337.64M |
June 30, 2021 | 272.28M |
March 31, 2021 | 192.45M |
December 31, 2020 | 208.98M |
September 30, 2020 | 333.71M |
June 30, 2020 | 391.39M |
March 31, 2020 | 421.44M |
December 31, 2019 | 526.96M |
September 30, 2019 | 473.53M |
June 30, 2019 | 562.77M |
March 31, 2019 | 505.50M |
December 31, 2018 | 415.72M |
September 30, 2018 | 364.48M |
June 30, 2018 | 237.49M |
March 31, 2018 | 168.56M |
December 31, 2017 | 165.61M |
Date | Value |
---|---|
September 30, 2017 | 197.37M |
June 30, 2017 | 153.72M |
March 31, 2017 | 122.45M |
December 31, 2016 | 210.40M |
September 30, 2016 | 90.40M |
June 30, 2016 | 61.94M |
March 31, 2016 | 60.84M |
December 31, 2015 | -141.05M |
September 30, 2015 | -156.13M |
June 30, 2015 | -179.90M |
March 31, 2015 | -208.40M |
December 31, 2014 | -235.40M |
September 30, 2014 | -232.76M |
June 30, 2014 | -231.75M |
March 31, 2014 | -216.44M |
December 31, 2013 | -198.77M |
September 30, 2013 | -190.18M |
June 30, 2013 | -167.24M |
March 31, 2013 | -162.60M |
December 31, 2012 | -123.15M |
September 30, 2012 | -113.58M |
June 30, 2012 | -122.80M |
March 31, 2012 | -130.92M |
December 31, 2011 | -159.23M |
September 30, 2011 | -108.80M |
Cash From Operations Definition
Cash flow from operations is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall operating activities of the company. A few examples of operating activities include change in receivables, change in inventories, and changes in current assets.
Cash from Operations (TTM) Range, Past 5 Years
192.45M
Minimum
Mar 2021
562.77M
Maximum
Jun 2019
376.62M
Average
385.37M
Median
Sep 2022
Cash from Operations (TTM) Benchmarks
Regeneron Pharmaceuticals Inc | 4.594B |
Bristol-Myers Squibb Co | 13.86B |
Johnson & Johnson | 22.79B |
Bio-Techne Corp | 276.43M |
Legend Biotech Corp | -393.28M |